We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
BioNTech, Genmab Launch Up-to-$15M Collaboration
News

BioNTech, Genmab Launch Up-to-$15M Collaboration

BioNTech, Genmab Launch Up-to-$15M Collaboration
News

BioNTech, Genmab Launch Up-to-$15M Collaboration

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "BioNTech, Genmab Launch Up-to-$15M Collaboration"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

The collaboration represents BioNTech’s second focused on cancer immunotherapy in as many weeks. On May 11, BioNTech launched an up-to-$360 million partnership with Eli Lilly to identify and validate new tumor targets and their corresponding T cell receptors (TCRs) in one or more undisclosed types of cancer.

In the latest alliance with Genmab, BioNTech said it will combine its immunomodulatory antibodies and onco-immunotherapy expertise with Genmab's DuoBody® technology platform, which uses a three-step process to produce, purify, and recombine a pair of human IgG1 antibodies. Genmab says DuoBody can be applied toward both drug discovery and large-scale development of bispecific antibodies specifically designed to stimulate the immune system against cancer.

Genmab has agreed to pay BioNTech a $10 million upfront fee, plus potential near-term payments of up to $5 million if BioNTech assets are nominated for further development. The companies have agreed to share equally development and commercialization costs, together with product ownership.

Should either company not wish to move a product candidate forward, the other is entitled to continue developing the product on predetermined licensing terms encompassing development and commercialization milestones and royalties on net sales, the companies said. The agreement also includes provisions which will allow the companies to opt out of joint development at key points.

Publicly-traded Genmab said the collaboration with privately-held BioNTech will not affect previously-disclosed guidance to investors.

Advertisement